Vertex Pharmaceuticals Inc のコンセンサス目標株価は $489.17 で、26 人のアナリストの評価に基づいています。最高値は $575(10 2, 2025 に Citigroup が発表)、最安値は $411(8 6, 2025 に Canaccord Genuity が発表)です。直近のアナリスト評価 3 件は UBS、RBC Capital、Barclays により 11 7, 2025、11 4, 2025、11 4, 2025 に発表されました。UBS、RBC Capital、Barclays の平均目標株価は $458.33 で、これらの最新評価から Vertex Pharmaceuticals Inc に対して 11.65% のupsideが示唆されています。
1アナリスト評価から算出
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/07/2025 | 33.01% | UBS | $553 → $546 | Maintains | Buy | |||
11/04/2025 | 1.1% | RBC Capital | $423 → $415 | Maintains | Sector Perform | |||
11/04/2025 | 0.85% | Barclays | $408 → $414 | Maintains | Equal-Weight | |||
11/04/2025 | 8.4% | Stifel | $455 → $445 | Maintains | Hold | |||
10/10/2025 | 6.7% | Morgan Stanley | $439 → $438 | Maintains | Equal-Weight | |||
10/08/2025 | 29.11% | JP Morgan | $517 → $530 | Maintains | Overweight | |||
10/02/2025 | 40.07% | Citigroup | $550 → $575 | Maintains | Buy | |||
09/25/2025 | 11.08% | Leerink Partners | $458 → $456 | Upgrade | Market Perform → Outperform | |||
09/11/2025 | 15.71% | Evercore ISI Group | $510 → $475 | Maintains | Outperform | |||
09/03/2025 | — | Raymond James | — | Initiates | → Market Perform | |||
08/07/2025 | 33.98% | Citigroup | $575 → $550 | Maintains | Buy | |||
08/06/2025 | 0.12% | Canaccord Genuity | $424 → $411 | Maintains | Hold | |||
08/06/2025 | 33.01% | Guggenheim | $558 → $546 | Maintains | Buy | |||
08/06/2025 | 12.06% | Wells Fargo | $460 → $460 | Upgrade | Equal-Weight → Overweight | |||
08/05/2025 | 19.37% | Truist Securities | $520 → $490 | Maintains | Buy | |||
08/05/2025 | 6.7% | Scotiabank | $442 → $438 | Maintains | Sector Perform | |||
08/05/2025 | 29.11% | BMO Capital | $557 → $530 | Maintains | Outperform | |||
08/05/2025 | -1.34% | RBC Capital | $430 → $405 | Maintains | Sector Perform | |||
08/05/2025 | 34.71% | UBS | $582 → $553 | Maintains | Buy | |||
08/05/2025 | 10.84% | Stifel | $494 → $455 | Maintains | Hold | |||
08/05/2025 | 18.15% | Cantor Fitzgerald | $535 → $485 | Maintains | Overweight | |||
08/05/2025 | 6.94% | Morgan Stanley | $460 → $439 | Maintains | Equal-Weight | |||
08/05/2025 | 16.44% | HC Wainwright & Co. | $550 → $478 | Maintains | Buy | |||
07/14/2025 | 25.94% | JP Morgan | $515 → $517 | Maintains | Overweight | |||
06/23/2025 | 33.98% | HC Wainwright & Co. | $550 → $550 | Reiterates | Buy → Buy | |||
06/20/2025 | 12.06% | Morgan Stanley | $464 → $460 | Maintains | Equal-Weight | |||
06/17/2025 | 2.31% | RBC Capital | $423 → $420 | Maintains | Sector Perform | |||
05/06/2025 | 3.05% | RBC Capital | $420 → $423 | Maintains | Sector Perform | |||
05/06/2025 | 7.67% | Scotiabank | $450 → $442 | Maintains | Sector Perform | |||
05/06/2025 | 13.03% | Morgan Stanley | $462 → $464 | Maintains | Equal-Weight | |||
05/06/2025 | 25.46% | JP Morgan | $512 → $515 | Maintains | Overweight | |||
05/06/2025 | 30.33% | Cantor Fitzgerald | $535 → $535 | Reiterates | Overweight → Overweight | |||
05/06/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
05/06/2025 | 22.53% | Leerink Partners | $550 → $503 | Downgrade | Outperform → Market Perform | |||
04/22/2025 | 30.33% | Cantor Fitzgerald | → $535 | Assumes | → Overweight | |||
04/01/2025 | 2.31% | RBC Capital | $408 → $420 | Maintains | Sector Perform | |||
03/31/2025 | 38.12% | B of A Securities | $555 → $567 | Maintains | Buy | |||
02/20/2025 | -0.61% | RBC Capital | $407 → $408 | Maintains | Sector Perform | |||
02/12/2025 | 3.29% | Canaccord Genuity | $408 → $424 | Upgrade | Sell → Hold | |||
02/11/2025 | 42.02% | UBS | $586 → $583 | Maintains | Buy | |||
02/11/2025 | 35.2% | B of A Securities | $540 → $555 | Maintains | Buy | |||
02/11/2025 | 26.67% | Truist Securities | $460 → $520 | Maintains | Buy | |||
02/11/2025 | -0.85% | RBC Capital | $402 → $407 | Maintains | Sector Perform | |||
02/11/2025 | 9.62% | Scotiabank | $433 → $450 | Maintains | Sector Perform | |||
02/11/2025 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
02/11/2025 | 13.76% | Barclays | $435 → $467 | Maintains | Equal-Weight | |||
02/11/2025 | 33.98% | HC Wainwright & Co. | $550 → $550 | Reiterates | Buy → Buy | |||
02/11/2025 | 11.81% | Morgan Stanley | $450 → $459 | Maintains | Equal-Weight | |||
02/11/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
02/04/2025 | 31.55% | B of A Securities | $522 → $540 | Maintains | Buy | |||
01/31/2025 | 5.97% | Barclays | $418 → $435 | Maintains | Equal-Weight | |||
01/31/2025 | 32.76% | BMO Capital | $520 → $545 | Maintains | Outperform | |||
01/31/2025 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
01/31/2025 | 5.48% | Scotiabank | $430 → $433 | Maintains | Sector Perform | |||
01/31/2025 | 33.98% | HC Wainwright & Co. | $535 → $550 | Maintains | Buy | |||
01/31/2025 | — | Needham | — | Reiterates | Hold → Hold | |||
01/30/2025 | 12.06% | Wells Fargo | $460 → $460 | Downgrade | Overweight → Equal-Weight | |||
01/27/2025 | 29.84% | Piper Sandler | $535 → $533 | Maintains | Overweight | |||
01/24/2025 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
01/10/2025 | 11.08% | Morgan Stanley | $476 → $456 | Maintains | Equal-Weight | |||
01/10/2025 | 12.06% | Wells Fargo | $555 → $460 | Maintains | Overweight | |||
12/23/2024 | 12.06% | Truist Securities | $550 → $460 | Maintains | Buy | |||
12/23/2024 | 4.75% | Scotiabank | $426 → $430 | Maintains | Sector Perform | |||
12/23/2024 | 21.8% | JP Morgan | $503 → $500 | Maintains | Overweight | |||
12/20/2024 | -2.56% | RBC Capital | $451 → $400 | Maintains | Sector Perform | |||
12/20/2024 | 1.83% | Barclays | $509 → $418 | Maintains | Equal-Weight | |||
12/20/2024 | 26.67% | BMO Capital | $566 → $520 | Maintains | Outperform | |||
12/20/2024 | — | Needham | — | Reiterates | Hold → Hold | |||
12/20/2024 | 30.33% | HC Wainwright & Co. | $600 → $535 | Maintains | Buy | |||
12/19/2024 | — | Oppenheimer | — | Downgrade | Outperform → Perform | |||
12/19/2024 | 27.16% | B of A Securities | $545 → $522 | Maintains | Buy | |||
12/16/2024 | 20.34% | Stifel | $490 → $494 | Maintains | Hold | |||
12/09/2024 | 33.98% | Jefferies | $500 → $550 | Upgrade | Hold → Buy | |||
11/14/2024 | 40.07% | Citigroup | → $575 | Initiates | → Buy | |||
11/06/2024 | -0.61% | Canaccord Genuity | $361 → $408 | Maintains | Sell | |||
11/05/2024 | 18.39% | Scotiabank | $480 → $486 | Maintains | Sector Perform | |||
11/05/2024 | 42.75% | UBS | $562 → $586 | Maintains | Buy | |||
11/05/2024 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
11/05/2024 | 9.87% | RBC Capital | $437 → $451 | Maintains | Sector Perform | |||
11/05/2024 | 22.53% | JP Morgan | $510 → $503 | Maintains | Overweight | |||
11/05/2024 | 15.96% | Morgan Stanley | $473 → $476 | Maintains | Equal-Weight | |||
10/30/2024 | 31.55% | Oppenheimer | $550 → $540 | Maintains | Outperform | |||
10/21/2024 | 46.16% | HC Wainwright & Co. | $600 → $600 | Reiterates | Buy → Buy | |||
10/17/2024 | 36.91% | UBS | $477 → $562 | Maintains | Buy | |||
10/16/2024 | 16.93% | Scotiabank | → $480 | Initiates | → Sector Perform | |||
10/14/2024 | 31.79% | B of A Securities | $550 → $541 | Maintains | Buy | |||
10/10/2024 | — | Raymond James | — | Reinstates | → Market Perform | |||
10/09/2024 | 6.46% | RBC Capital | $425 → $437 | Maintains | Sector Perform | |||
10/08/2024 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight | |||
10/04/2024 | 3.53% | RBC Capital | $431 → $425 | Maintains | Sector Perform | |||
10/01/2024 | 15.47% | Morgan Stanley | $462 → $474 | Maintains | Equal-Weight | |||
09/19/2024 | 4.99% | RBC Capital | $431 → $431 | Reiterates | Sector Perform → Sector Perform | |||
08/05/2024 | 46.16% | HC Wainwright & Co. | $500 → $600 | Maintains | Buy | |||
08/05/2024 | 33.98% | Oppenheimer | $500 → $550 | Maintains | Outperform | |||
08/05/2024 | 24.24% | JP Morgan | $505 → $510 | Maintains | Overweight | |||
08/05/2024 | 33.98% | Truist Securities | $508 → $550 | Reiterates | Buy → Buy | |||
08/05/2024 | 24% | Barclays | $472 → $509 | Downgrade | Overweight → Equal-Weight | |||
08/02/2024 | 25.46% | Evercore ISI Group | $438 → $515 | Maintains | Outperform | |||
08/02/2024 | 35.93% | Guggenheim | $450 → $558 | Maintains | Buy | |||
08/02/2024 | 16.93% | Cantor Fitzgerald | $480 → $480 | Reiterates | Overweight → Overweight |
Vertex Pharmaceuticalsの最新目標株価Vertex Pharmaceuticals。(NASDAQ:VRTX) の最新目標株価をUBSが11 7, 2025日に発表した。このアナリスト会社はVertex Pharmaceuticals ({{change}:{{mbol}}) {{{quoteName}}の{{change}:{{symbol}}からriseまで12ヶ月以内(33.01% upsideの可能性あり)と予想する$546.00の目標株価を設定しました。過去1年間に74のアナリスト会社がレーティングを報告しています。
Vertex Pharmaceuticalsの最新のアナリストレーティングはVertex Pharmaceuticalsです。(NASDAQ:VRTX) の最新のアナリストレーティングはUBSによるもので、Vertex PharmaceuticalsのVertex Pharmaceuticalsです。{actionCompany}}のbuy評価です。
Vertex Pharmaceuticals Incの最後のアップグレードは9 25, 2025日に行われ、Leerink Partnersは目標株価を$456に引き上げました。companyName}}のLeerink Partnersの以前のa market performは$456でした。
Vertex Pharmaceuticals Incの最後の格下げは5 6, 2025日にLeerink PartnersがVertex Pharmaceuticals Incの目標株価を$550から$503に変更した時です。
アナリストは、公開財務諸表を調べたり、Vertex Pharmaceuticalsの役員や顧客に話を聞いたり、決算の電話会議を傍聴したりと、広範な調査を行った上で株価の格付けを行っています。ほとんどのアナリストは3ヶ月ごとにこの作業を行いますので、毎年1社につき4つの格付けを得ることになります。companyName}}の最終レーティングは11 7, 2025日に提出されましたので、次のレーティングは11 7, 2026日あたりに提出されるものと思われます。
レーティングは主観的なものであり変化しますが、最新のVertex Pharmaceuticals (VRTX) (VRTX) のレーティングは維持で、目標株価は$553.00から$546.00でした。現在の価格 Vertex Pharmaceuticals ({{exchange}}) (VRTX) の現在の取引価格は$410.50で、これはアナリストの予測レンジout ofです。
ブラウズ アナリスト評価と目標株価 全銘柄の
